INTRODUCTION
O'-Alkylguanine-DNA alkyltransferase (AGT) is an important DNA repair protein which is able to protect cells from the mutagenic and toxic effects of monofunctional alkylating agents and some chloroethylating drugs [1] [2] [3] [4] [5] . It acts to repair O'-alkylguanine residues formed in DNA by these agents. Repair is carried out by the transfer of the alkyl group from the DNA to an active-site cysteine residue of the AGT protein itself resulting in the restoration of the DNA structure in a single step. The Salkylcysteine formed at the active site of AGT is not converted back into cysteine ; the protein, therefore, can act only once. The alkylated form of the AGT protein undergoes a conformational change, which leads to its rapid degradation, possibly by facilitating its ubiquitinylation [6] [7] [8] .
AGT genes have been found in many living systems, including Eubacteria, Archaea and Eucarya. At least 28 DNA sequences coding for AGT genes representing 25 different species have now been reported. There are approx. 30 residues in these sequences that are either absolutely invariant or have only a small number of very conservative changes. These highly conserved amino acids are located in the carboxyl half of the protein, which includes the DNA-binding domain and the cysteine acceptor site [9] [10] [11] (Figure 1 ). Based on the alkyltransferase crystal structure [12] [13] [14] , models of the binding of the DNA substrate to the protein, and studies of the reaction mechanism [9, 15, 16] , it is likely that the O'-alkylguanine residue is flipped out of the DNA helix and bound in an active-site pocket containing the Cys-145 acceptor.
Abbreviations used : AGT, O 6 -alkylguanine-DNA alkyltransferase ; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea ; BG, O 6 -benzylguanine ; DTT, dithiothreitol ; LB, Luria-Bertani ; MNNG, N-methyl-Nh-nitro-N-nitrosoguanidine ; WT, wild-type ; ED 50 , the amount of inhibitor needed to produce a 50 % loss of activity in a 30 min incubation. 1 To whom correspondence should be addressed (e-mail aep1!psu.edu).
showed 620-fold and 100-fold increases in resistance to BG. Two mutants at the Ser"&* position (S159I and S159V) were 80-fold more resistant than wild-type AGT. Eleven active mutants at Leu"'* were also resistant to BG, but with lower increases (5-86-fold). Fourteen BG-resistant mutants were found for position Cys"&!, with 3-26-fold increases in the amount of inhibitor needed to produce a 50 % loss of activity in a 30 min incubation. Six BG-resistant mutants at Asn"&( were found with increases of 4-13-fold. These results show that many changes can render human AGT resistant to BG without preventing the ability to protect tumour cells from therapeutic alkylating agents.
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Human AGT is rapidly inactivated by reaction with O'-benzylguanine (BG) [17] . The mechanism of this inactivation is well understood and involves the recognition of BG as a substrate by the AGT. BG is bound at the active site, where the benzyl group is transferred, releasing guanine and forming S-benzylcysteine in the AGT protein [18] . In animal models, BG has been shown to enhance the cancer chemotherapeutic effects of chloroethylating agents, such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and methylating agents, such as temozolomide [4, 19, 20] . BG is currently in Phase II trials for use as an antitumour agent [21, 22] .
However, BG is not effective as an inactivator of the AGT proteins from Escherichia coli and yeast [18, 23, 24] . This is probably due to the steric exclusion of BG from the active-site pocket [14] , consisting of the residues shown in Figure 1 . Mutation of two residues in the E. coli Ada-C AGT sequence (equivalent to the replacement of alanine with proline at position 140 and the substitution of the tryptophan at position 156 with glycine or alanine) increases the space available at the active site and renders this C-terminal domain of the Ada gene product capable of reacting with BG [25, 26] . These results suggest that alterations in human AGT are possible which reduce the ability of the protein to react with BG, without eliminating activity towards alkylated DNA substrates. Several mutants have been produced that support this hypothesis. Single point mutations at Pro"$), Pro"%!, Gly"&', Tyr"&) and Gly"'! have all been shown to be associated with resistance to BG [27] [28] [29] [30] . A detailed study of mutants of the region Pro"$)Val"$*Pro"%!, on the N-terminal side of the active site, has determined that any replacement of
Figure 1 AGT sequence surrounding the active site
The residues corresponding to the human AGT sequence from Asn 137 to His 174 , which contains the cysteine acceptor site at residue 145, are shown for the 28 known AGT sequences. Highly conserved consensus residues and the residues with conservative alterations at these consensus positions are shaded in black.
Pro"%! renders AGT resistant to BG, although insertion of the basic residues, such as lysine and arginine, is most effective [31] . Human AGT mutants with multiple changes, some involving these sites, have also been reported to be strongly BG-resistant [32, 33] .
In the present study, we have carried out a detailed analysis of the residues from 150 to 173 in human AGT. This region was chosen because, along with previously examined residues 138-140 [31] , it makes up a large part of the binding pocket for the substrate base. A plasmid-expression library was constructed in which each of these individual residues in the 150-173 region were randomly mutated, and the AGT was expressed in E. coli. The bacteria containing active but BG-resistant AGT mutants were then selected by exposure to BG and N-methyl-Nh-nitro-Nnitrosoguanidine (MNNG). This screening revealed that many sites could be mutated to yield BG-resistant AGTs. So many mutants were obtained in this screen that it was necessary to use libraries with more limited alterations in order to get a more complete collection of such BG-resistant mutants at any particular site. Such detailed studies were carried out with mutants formed at Cys"&!, Gly"&', Asn"&(, Leu"') and Leu"'*. These results, and those in the accompanying paper in which mutants at Lys"'& were examined [34] , show that numerous amino acid substitutions affect the ability of human AGT to accept BG at the active site, without impairing the ability to repair alkylated DNA. The facile appearance of BG-resistant mutants may therefore be a significant problem in the clinical development of this drug.
EXPERIMENTAL Materials
All oligodeoxyribonucleotides were purchased from Life Technologies, E. coli strain TRG8 was derived from strain GWR109 [35] , which was kindly provided by Dr L. Samson [31] and pUC-inAGT2 [30] were made as previously described.
Construction and selection of random libraries containing individual mutations from codon Cys 150 to Gly 173
The random library covering codons 150-173 was designed to contain only single amino acid changes. The DNA insert was created by PCR covering the region from nt 420-540, including the DraIII site (at 436) and the AgeI site (at 521). Twenty-four individual PCR products were synthesized using pUC-AGTm as a template, and each contained amino acid sequences replaced with random nucleotide sequences using the primers listed in Table 1 . Eleven PCR products, including C150X to G160X, used the 5h-GGCTTCCCCAACCGGTGGCC-3h (AgeI site in italics) as the common antisense primer, while the other 13 PCR products, including G161X to G173X, used the 5h-CCGTGC-CACAGAGTGG-3h (DraIII site in italics) as the common sense primer. The PCR reactions were carried out using the following conditions : initial denaturation for 2 min at 92 mC ; 30 cycles of denaturation (1 min at 92 mC) ; annealing (1 min at 54 mC) ; extension (1 min at 72 mC) ; followed by a final extension at 72 mC for 5 min. The 24 PCR products were individually gel purified using the Gel Extraction Kit (Qiagen), quantified by UV spectrophotometry, combined in equal amounts, digested with DraIII and AgeI enzymes, and ligated into pUC-inAGT2 digested with the same enzymes. The random libraries in which one or two amino acids were substituted with random nucleotide sequences (C150X, S159X, L168X, L169X and G156X\N157X) were made by inserting two (for G156X\N157X) or one (for the rest of the libraries) PCR products corresponding to the above changes into the pUC-inAGT2 plasmid digested with the same enzymes. The ligated products were transformed into XL1-Blue cells ; an aliquot of the transformation mixture was plated on LuriaBertani (LB) plates, supplemented with 50 µg\ml ampicillin to determine the number of plasmid-containing bacteria (3.6i10' for the C150-G173 library, 1.0i10& for the C150X, S159X, L168X, L169X libraries and 1.2i10' for the G156X\N157X library), and the remainder were amplified by growing overnight. The plasmid DNA was isolated from the overnight cultures,
Table 1 Primers used for construction of the C150-G173 library
Mismatches are underlined, restriction sites are shown in italics.
Mutation Primer
subjected to sequencing analysis to confirm that the randomized sequence was present, and introduced into the TRG8 strain by electroporation. An aliquot of the second transformant mixture was plated to determine the total number of available transformants, which was 2i10), and the rest was amplified overnight in LB medium containing ampicillin and kanamycin (50 µg\ml each). Aliquots of this library were subjected to the screening process or stored at k70 mC for further use. Active and BG-resistant alkyltransferase mutants were selected by treating exponentially growing random-library-transformed-TRG-8 bacteria (A '!! l 0.5) with 50 µM BG for 1.5 h, followed by 40 µg\ml MNNG for 0.5 h at 25 mC, as described in [31] . Plasmid DNA was isolated from individual surviving colonies and subjected to sequencing analysis. Crude extracts for determination of AGT activity were prepared from each novel mutant grown overnight in 10 ml LB medium by sonicating the bacteria pellet resuspended in 50 mM Tris\HCl (pH 7.5), 0.1 mM EDTA and 5 mM dithiothreitol (DTT) for 2 min at 0 mC using an ultrasonic cell disruptor (model W-225-R ; Misonix Inc., Farmingdale, NY, U.S.A.) on pulse setting 50 % duty cycle. Cell debris was pelleted by centrifugation at 4 mC for 15 min at 15 000 g, and the supernatant was used to determine the alkyltransferase activity level and its sensitivity to BG.
Determination of the effects of BG on AGT activity
Inactivation of the AGT activity by BG in crude bacterial extracts was measured by incubating aliquots of the protein with different concentrations of BG at 37 mC for 30 min in 0.5 ml of 50 mM Tris\HCl (pH 7.6), 5 mM DTT, 0.1 mM EDTA containing 50 µg of haemocyanin and 10 µg of calf-thymus DNA. The residual AGT activity was determined by incubating the samples with [$H]methylated DNA substrate for 30 min at 37 mC and measuring [$H]methylated protein formed after collection on nitrocellulose filters [31] . The results were expressed as the percentage of the AGT activity remaining. Plots of remaining AGT activity versus inhibitor concentration were used to calculate an ED &! value representing the amount of inhibitor needed to produce a 50 % loss of activity.
Purification of mutant proteins
Recombinant wild-type (WT), G160R and P140A mutant AGTs were expressed using the pQE vector, which adds a 12 amino acid sequence (MRGS [H] ' GS-) to the N-terminus of the AGT protein, and purified by immobilized metal-affinity chromatography as previously described [29] .
RESULTS

Screening of AGT residues 150-173
In order to investigate the role of residues 150-173 of human AGT on its activity and reactivity to BG, a plasmid library was constructed to contain random sequences replacing each of the 24 amino acids. Each residue was randomly mutated to NNG\C during PCR synthesis. The use of the NNG\C sequence reduces the chances of inserting a stop codon and also provides a more even representation of the different amino acids [36] . However, three of the amino acids (arginine, leucine and serine) are still each represented by three codons, five amino acids (alanine, glycine, proline, threonine and valine) are represented by two codons, and the remaining 12 possibilities have only one codon each. The PCR products containing mutations for 24 residues were individually purified, combined at equal amounts and ligated into the pUC plasmid for expression in E. coli. The pUC vector was used because it gives only a low level of expression of the AGT proteins. This permits the use of BG to abolish the protection of the cells from killing by MNNG [31] . The library was expressed in the E. coli strain TRG8, which is deficient in endogenous alkyltransferase activity and permeable to BG [31] , 
and contained at least 3.6i10' transformants, which provided a sufficient source to include all 20 amino acids for each residue.
After selection of this library with 40 µg\ml MNNG and 50 µM BG, the AGT cDNA inserts in the plasmids isolated from 107 of the surviving colonies were analysed. Two of these clones did not produce AGT [an amber mutation (E166Stop) and religated vector sequence with no functional AGT gene]. Of the other 105 clones, 70 different AGT mutants (Table 2 ) and WT AGT were found. AGT activity was measurable using 200 µg of crude protein extract for every mutant. The sensitivity of the mutants to BG was determined as ED &! values. Because of the large number of candidate mutants, it was not feasible to purify the AGT protein. Therefore, the assays were carried out using crude protein extracts. In order to check that the other proteins present in these extracts did not influence the results, studies were conducted using purified WT AGT (ED &! 0.1 µM) and two known mutants with moderate resistance to BG, G160R (ED &! 4.7 µM) and P140A (ED &! 4 µM). Extracts from the control TRG8 E. coli strain that lacks endogenous AGT were added to these proteins and assays were then carried out. Homogeneous preparations of these AGT proteins were tested in the standard assay system with the addition of no extract, 6 µg of E. coli extract, or 200 µg of E. coli extract. The ED &! values were not altered significantly (by less than a factor of two, which is probably within experimental error) by the presence of the E. coli extract.
There were 17 clones expressing WT AGT sequences and 8 clones (6 mutants) that had ED &! values for inactivation by BG of 0.1 µM, which are identical with WT AGT. These are clearly false positives. There were also 12 clones (12 mutants), which had 70 mutants found (74 %) were definitively BG-resistant. These mutants were distributed widely, including 19 different amino acid positions in the 24 residues between Cys"&! and Gly"($. Thus mutations at most of the residues in this region may lead to significantly increased ED &! values for BG. No substitutions were found for Tyr"&), Leu"') and Glu"(#, and these residues are highly conserved among all alkyltransferase proteins (Figure 1 ). Some substitutions were found for other well-conserved residues, such as Lys"'& and Leu"'*. This indicates that changes can be made at these positions without losing all AGT activity, but these mutants were less active in comparison with WT AGT, in that a higher amount of crude bacterial extract was needed to repair the same amount of DNA substrate (Table 3) .
Mutations at residues Gly"&' and Lys"'& resulted in the largest increase in resistance to BG with at least 100-fold higher ED &! values. These two positions, as well as Asn"&(, Cys"&!, Leu"'* and Leu"') (see below), were studied in more detail. Since so many alterations render AGT resistant to BG, this analysis was conducted using libraries in which a more limited number of residues were altered.
Mutants at Gly 156
Five alterations at Gly"&' found in the general screen rendered AGT highly resistant to BG (Table 3) . These results are consistent with previous studies in which two mutations (G156A and G156W) at Gly"&', including one found in the current screen (G156W), were reported to cause the AGT protein to become resistant to BG [28] . In order to examine this position in more detail, a library was constructed containing random mutations for each of the two residues, Gly"&' and Asn"&(. Mutants from this library of a pool of 1.2i10' members were selected with BG and MNNG. The AGT cDNA inserts in the plasmids isolated from 22 of the surviving colonies were analysed. Sixteen clones (73 %) contained mutations at Gly"&', and the remainder contained mutations at Asn"&(. The mutants at position 156 are shown in Table 4 .
A total of 11 mutants at Gly"&' were identified, and all were highly BG-resistant with at least 190-fold higher ED &! values than WT AGT. The replacement with proline produced the biggest increase in ED &! with a 4000-fold increase. However, substitutions found included hydrophobic and hydrophilic, including positively charged, residues. No acidic residues were found. Glutamine and asparagine residues were also absent. It is possible that these changes are not compatible with AGT activity. In all cases, the amount of bacterial protein needed to get 80 % repair of the methylated DNA substrate used was increased 10-30-fold over that needed with extracts expressing WT AGT (Table 4) .
Mutants at Asn 157
In the general screen three mutants, N157G, N157E and N157W, were found to impart increases in resistance to BG with ED &! values increased by up to 13-fold. Eight mutants at Asn"&( were identified in the screening of the joint G156X\N157X library. These provided another 3 alterations resulting in resistance. Most of the mutants at position Asn"&( were almost as active as WT AGT in repairing methylated DNA (Table 5) . Six of these mutants were BG-resistant ; however, none resulted in reductions in the sensitivity to BG as large as those found with alterations at position 156. The increases in ED &! values from N157X ranged from 4 to 13-fold (Table 5 ). This may be relevant to the observations that the mouse AGT is less sensitive (by approx. 5-fold) to BG than the human or the rat AGT, even though these proteins are very similar over the entire coding sequence [24, 37] . Position 157 is one of the few places in the region studied which varies in these species in a manner related to the sensitivity to BG, being asparagine in the rat and human AGTs, but histidine in the mouse AGT.
Mutants at Cys 150
Four BG-resistant mutants at position Cys"&! were found in the initial screen. A further ten mutants (plus WT AGT) were isolated by selection with BG and MNNG from a C150X library (Table 6 ). All of the mutants were resistant to BG with increases in ED &! values from 3-to 26-fold. The largest increases were produced with bulky amino acid replacement such as tyrosine, phenylalanine and tryptophan, whereas alterations to glycine, serine and threonine produced the least increase in BG-resistance. The alterations at Cys"&! produced only small increases in the amount of protein needed to repair 80 % of the methylated DNA substrate used in the standard assay, suggesting that there was little, if any, alteration in the stability of the protein or of the ability to repair alkylated DNA. † The maximum of protein that can be used in the assay is 0.2 mg. This gave less than 80 % removal of O 6 -methylguanine and the amount removed is shown in parentheses. ‡ The AGT activity level was too low for accurate assays with crude extracts prepared under the standard conditions. Therefore, the bacterial cultures were grown in the presence of 0.15 mM isopropyl β-D-thio galactoside to increase AGT expression. These extracts were then used for the assay. The expression of AGT obtained in the presence of isopropyl β-D-thio galactoside with these conditions is increased about 4-fold.
Mutants at Leu 169
Five BG-resistant mutants at position Leu"'* were found in the initial screen of the library (Table 3) . A further 5 mutants were isolated from a L169X library by selection with BG and MNNG, and 4 additional mutants were obtained by taking clones from the library without selections. All of these mutants assayed were also BG-resistant (Table 7 ). These 11 mutants had ED &! values increased 5-86-fold. Most of the mutants found at this position were substantially less active than WT AGT. Three of the mutants isolated (L169D, L169C and L169G) had insufficient activity for assay of an ED &! value for BG inactivation. Since these mutants were all isolated after selection with MNNG and BG, it is likely that they did have activity in i o and can protect † Even when extracts were grown in the presence of isopropyl β-D-thiogalactoside there was insufficient AGT activity for determination of an ED 50 value. The maximum protein that can be used in the assay is 0.2 mg. This gave less than 80 % removal of O 6 -methylguanine. The amount removed is shown in parentheses.
the host E. coli. However, this activity is too low or too unstable to be measured in crude cell extracts. The only 3 mutants with activities towards methylated DNA close to WT were replacements with isoleucine, phenylalanine and tyrosine. These alterations were among those having the lowest increases in BGresistance, but there was still a 5-8-fold increase in the ED &! value.
Mutants at Leu 168
There are 3 highly conserved residues (Tyr"&), Leu"') and Glu"(#) in the Cys"&!-Gly"($ region in which no mutants were found in the screen of this library (Figure 1 ). It is likely that only a few permissible substitutions that lead to active AGT exist for these residues, and the even more limited BG-resistant subset may not have been found due to the limited numbers of clones screened. Positions Tyr"&) and Glu"(# have been investigated previously by site-directed mutagenesis. Glu"(# appears to be important for the structure\function of AGT, and even replacement with glutamine greatly reduces AGT activity and stability [38, 39] . The only replacements for Tyr"&) that give active AGT are phenylalanine (which is not BG-resistant) [40] and histidine (which is highly BG-resistant) [30] .
Position Leu"') had not been investigated previously so a library in which only the codon 168 was mutated was screened using MNNG alone to identify any active AGT mutants. Twentyone clones were isolated. These included 5 WT sequences. The mutants found were changes to cysteine (6 clones), methionine (4 clones), isoleucine (3 clones), serine (2 clones) and phenylalanine (1 clone). The L168S mutant gave a very low activity in the E. coli extracts (Table 7) . These results suggest that a hydrophobic amino acid at position 168 is needed to give active AGT. The 4 mutants that could be assayed were resistant to BG but had only small (4-5-fold) increases in ED &! values (Table 8) .
DISCUSSION
The procedure used for the selection of active but BG-resistant mutants from the library of plasmids expressing AGT altered in the Cys"&!-Gly"($ region was successful in that most of the surviving clones contained AGT that was both active and BGresistant. However, there were a number of false positives. All but two of these had either WT or AGT mutants with ED &! values of 0.2 µM or less, and it is likely that they were found because the stringency of the selection was not high enough to exclude them. Higher stringency could be achieved by increasing the concentration of BG used in selection but this may also eliminate the selection of mutants that are only moderately resistant to BG.
Although all of the studies reported in this paper were carried out with crude cell extracts containing the mutant AGTs, the results are highly consistent with the limited number of previous studies in which purified AGT protein was used or the AGT was expressed in mammalian cells. Thus mutants G165A, G165W, G160R and K165A have all been shown to have similar ED &! values when assayed in crude extracts or with purified protein, and to protect mammalian cells from alkylating agents even in the presence of BG [29, 34, 41, 43] . Many sites were found to lead to BG-resistance when mutated. For this reason it would be necessary to isolate and sequence a very large number of clones in order to have a complete representation of mutants with BGresistant AGT activity. It should be noted that two of the positions (Leu"') and Tyr"&)), not found in general screening to be sites at which BG-resistance can occur, are actually positions in which BG-resistant mutants have been found. As shown in Table  8 , the conservative alterations at position Leu"') that yielded active AGT protein did impart a small degree of resistance to BG. The alteration of Tyr"&) to histidine (which is one of only two alterations tolerated at this position) produces a huge increase in ED &! for BG (from 0.1 µM to 620 µM) [30] . The reason that these mutants were not found is probably that they represent only a small percentage of the total mutants that provide protection under the screening conditions used.
Some of the AGT mutants found in the screen appeared to have a reduced activity towards methylated DNA, as indicated by the amount of bacterial extract needed for the assay, whereas others were close to WT in activity. In general, those mutants that were very highly resistant to BG had low activity and those that had only moderate resistance were more active. This may be a consequence of the screening procedure, where the residual activity in the presence of BG forms the major parameter for survival. This residual activity would be related to both the activity of AGT mutant (which is discussed below) and its sensitivity to BG. This is well illustrated by the screening of the complete library and the mixed G156X\N157X library. Of 38 mutations at the two sites, 24 were at Gly"&' and 14 at Asn"&(. Even though mutants at Gly"&' were 100-fold more resistant to BG than mutants at Asn"&(, they were also much less active when crude cell extracts were tested. Previous experiments with AGT mutants altered in the DNA-binding domain have shown that mutants in which the rate constant is reduced substantially are still able to provide protection from MNNG [11] . WT AGT repairs alkylated DNA very rapidly and this rate may be in excess of that needed to promote cell survival.
It should be noted that a reduction in AGT activity in crude bacterial extracts might be due to a number of factors in addition to a reduced rate of methyl transfer. Other possibilities include : incorrect folding of part of the AGT protein leading to an inactive fraction of the population ; an increased rate of degradation of the AGT protein in E. coli leading to a reduced level of protein ; and a decreased stability of the protein leading to partial denaturation during preparation of the extracts. All of these factors may contribute to the need for greater amounts of crude bacterial protein in the assays. Previous studies have shown that mutations of residues involved in AGT structural integrity do cause an incorrect folding and\or rapid degradation of the protein [39, 44] .
The results of the library screening indicate that mutations of many residues (19 out of 24) in the Cys"&!-Gly"($ region may alter the sensitivity of AGT to BG. The BG-resistance of the Y158H mutant and the L168 mutants described above raises this number to 21 out of 24. The three-dimensional structure of human AGT [14] shows that many of these 24 residues are located near the active site of the protein and alterations would tend to exclude BG by steric effects and\or by disrupting the hydrophobic region that accommodates the BG. Virtually all alterations of Gly"&' or Lys"'& would be expected to cause minor structural distortions of the binding pocket that exclude BG.
The abundance of BG-resistant mutants occurring in this region raises concern in using BG to enhance chemotherapy by alkylating agents. Since these agents are themselves mutagenic, the possibility that BG-resistant forms of AGT may arise is a serious issue. Even though many of the BG-resistant mutants identified in our screen may have somewhat impaired AGT activity (as discussed above), the ability of the E. coli clones expressing these mutants to survive treatment with a methylating agent, and the ability of the G156A [41, 42, 45, 46] , P140K [43] and K165A [34] mutant AGTs to protect mammalian cells from BCNU, strongly suggest that the mutants would be effective in counteracting the actions of chemotherapeutic agents such as temozolomide and BCNU, even in the presence of BG. Furthermore, even modestly resistant mutants of AGT such as P140A and G160R, which have ED &! values increased by approx. 40-fold, have been shown to provide a very high level of survival in mammalian cells exposed to BCNU and BG at levels that far exceed the maximal concentrations of BG and its active metabolite 8-oxo-BG reached in clinical trials [22, 47] . Therefore most, if not all, of the BG-resistant mutants from the Cys"&!-Gly"($ region described here, and other mutants found in the Pro"$)-Pro"%! region [31] , are likely to impart resistance to BG therapy if produced in treated tumours. Thus at least 23 codons in the AGT gene are potential sites for the generation of resistance as a result of single amino acid changes. The recently published crystal structure of human AGT reveals that other regions in the AGT protein, such as part of the H4 helix (residues 129-136), are also close to the BG-binding pocket [14] and may also be targets for such mutants rendering resistance to BG. The development of alternative AGT inhibitors able to inactivate these resistant mutants should therefore be given a high priority.
